Dr. Erin Alice Farrish, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 300 S Church St, Middletown, MD 21769 Phone: 301-371-9000 Fax: 301-371-8905 |
News Archive
Administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival in a mouse model of unresectable pancreatic cancer.
Research shows that the severity of gout, rather than uric acid level, is significantly associated with changes in left ventricular diastolic function and left atrial volume.
'Personalised medicine' is the topic of a free public lecture at the University of Greenwich. Personalised medicine, or precision medicine, as it is sometimes known, is a key goal for 21st century healthcare. Currently, many medicines are either ineffective or unsafe in certain patient populations, whereas the aim for personalised medicine is to target the right treatment to the right patient group.
Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation.
› Verified 5 days ago